Eric Adjei Boakye1, Oluwole A Babatunde2, Maggie Wang3, Nosayaba Osazuwa-Peters4, Wiley Jenkins5, Minjee Lee5, Minjin Kim6. 1. Department of Population Science and Policy, Southern Illinois University School of Medicine, Springfield, Illinois; Simmons Cancer Institute, Southern Illinois University School of Medicine, Springfield, Illinois. Electronic address: eadjeiboakye49@siumed.edu. 2. Department of Psychiatry, Medical University of South Carolina, Charleston, South Carolina. 3. Saint Louis University School of Medicine, St. Louis, Missouri. 4. Department of Head and Neck Surgery and Communication Sciences, Duke University School of Medicine, Durham, North Carolina. 5. Department of Population Science and Policy, Southern Illinois University School of Medicine, Springfield, Illinois; Simmons Cancer Institute, Southern Illinois University School of Medicine, Springfield, Illinois. 6. Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Boston, Massachusetts.
Abstract
INTRODUCTION: This study explores how human papillomavirus vaccination initiation and completion among men and women aged 18-34 years varies by geographic region. METHODS: Data from the 2015-2017 Behavioral Risk Factor Surveillance System were analyzed. Geographic regions for the selected states were defined as South, Northeast, and Midwest/West. Human papillomavirus vaccination initiation was defined as receipt of ≥1 dose, and completion was defined as receipt of ≥3 doses. Weighted, multivariable logistic regression models estimated the association between geographic region and vaccine uptake, adjusting for sociodemographic, health, and healthcare factors. Analyses were performed in November 2019. RESULTS: A total of 18,078 adults were included in the study, 80% of whom resided in the South. The overall vaccination initiation rate was 23.4%, and the completion rate was 11.0%. Initiation was higher among those who resided in the Northeast (38.6%), followed by Midwest/West (23.8%), and lowest for those in the South (21.8%) (p<0.0001). Completion rates followed the same trend as initiation. In the adjusted models, compared with the adults residing in the Northeast, those living in the South were less likely to initiate (AOR=0.47, 95% CI=0.40, 0.55) and complete (AOR=0.56, 95% CI=0.46, 0.68) human papillomavirus vaccination. CONCLUSIONS: Human papillomavirus vaccine uptake was low for all regions, but vaccine uptake was significantly lower in the South region. This demonstrates the need to identify barriers specifically associated with the Southern population, which may include differing levels of education and insurance. Such work is especially pertinent because many Southern states face increased risk of human papillomavirus-associated cancers such as cervix and oral cavity and pharynx cancers.
INTRODUCTION: This study explores how human papillomavirus vaccination initiation and completion among men and women aged 18-34 years varies by geographic region. METHODS: Data from the 2015-2017 Behavioral Risk Factor Surveillance System were analyzed. Geographic regions for the selected states were defined as South, Northeast, and Midwest/West. Human papillomavirus vaccination initiation was defined as receipt of ≥1 dose, and completion was defined as receipt of ≥3 doses. Weighted, multivariable logistic regression models estimated the association between geographic region and vaccine uptake, adjusting for sociodemographic, health, and healthcare factors. Analyses were performed in November 2019. RESULTS: A total of 18,078 adults were included in the study, 80% of whom resided in the South. The overall vaccination initiation rate was 23.4%, and the completion rate was 11.0%. Initiation was higher among those who resided in the Northeast (38.6%), followed by Midwest/West (23.8%), and lowest for those in the South (21.8%) (p<0.0001). Completion rates followed the same trend as initiation. In the adjusted models, compared with the adults residing in the Northeast, those living in the South were less likely to initiate (AOR=0.47, 95% CI=0.40, 0.55) and complete (AOR=0.56, 95% CI=0.46, 0.68) human papillomavirus vaccination. CONCLUSIONS: Human papillomavirus vaccine uptake was low for all regions, but vaccine uptake was significantly lower in the South region. This demonstrates the need to identify barriers specifically associated with the Southern population, which may include differing levels of education and insurance. Such work is especially pertinent because many Southern states face increased risk of human papillomavirus-associated cancers such as cervix and oral cavity and pharynx cancers.
Authors: Jacqueline M Hirth; Yong-Fang Kuo; Jonathan M Starkey; Richard E Rupp; Tabassum H Laz; Mahbubur Rahman; Abbey B Berenson Journal: Vaccine Date: 2019-06-07 Impact factor: 3.641
Authors: Kahee A Mohammed; Christian J Geneus; Nosayaba Osazuwa-Peters; Eric Adjei Boakye; Betelihem B Tobo; Thomas E Burroughs Journal: J Adolesc Health Date: 2016-08-06 Impact factor: 5.012
Authors: Elissa Meites; Peter G Szilagyi; Harrell W Chesson; Elizabeth R Unger; José R Romero; Lauri E Markowitz Journal: MMWR Morb Mortal Wkly Rep Date: 2019-08-16 Impact factor: 17.586